Search
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalOne of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.
Eflepedocokin alfa
go.drugbank.com/drugs/DB16366Investigational[A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]
Cambinol
go.drugbank.com/drugs/DB15493ExperimentalThis activity is currently being investigated for its use as a cancer treatment.
Pyruvic acid
go.drugbank.com/drugs/DB00119ApprovedInvestigationalNutraceuticalAn intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
Antithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal...
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalSerplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.
Synonyms: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalIt offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749